Characteristics of Turkish colorectal cancer patients and bevacizumab preference.
Bildiriler > Özet Bildiri
Yazarlar: Irfan Cicin, Mahmut Gumus, Dogan Uncu, Metin Ozkan, Saadettin Kilickap, Tamer E. Elkiran, Abdurrahman Isikdogan, Aziz Karaoglu, Berna Oksuzoglu, Feyyaz Ozdemir, Hande Turna, Oguz Kara, Ozgur Ozyilkan, Merve Guducu, Alper Erdogan, Ruchan Uslu
Journal of Clinical Oncology, , , Uluslararası, Özet Bildiri, Wos, cilt 35, ss e15055-e15055
DOI: 10.1200/jco.2017.35.15_suppl.e15055
Özet
e15055 Background: The aim of this registry was to collect demographic, diagnostic, treatment, and outcome information about Turkish patients with colorectal cancer (CRC). Methods: It was designed as a multicenter, cross-sectional, non-interventional study conducted on new and previously diagnosed CRC cases applied to 28 medical oncology outpatient clinics between 2012 and 2015. A total of 7547 male (n = 4314) and female (n = 3233) patients > 18 years were included. Results: The mean age at diagnosis was 57.7±12.4 years. There was no familial or other primary cancer history in majority of patients. 22.9% of patients (n = 1579) were diagnosed at Stage 4. In 73,7% of patients (n = 5492), tumor was left-sided. Lymphovascular invasion was determined in 34.3% of patients, 87.6% had surgery. Liver-only metastasis rate was 53.1%. KRAS was tested in 717 of 1579 mCRC patients and mutation was positive in 39.3% of cases (n = 282). BRAF and KRAS tests were performed at 3.5% (n = 83) and 49.2% (n = 1158) for first line, whereas at 5.5% (n = 54) and 63.9% (n = 630) for second line metastatic treatments, respectively. In 25,5% of stage 4 bevacizumab users, bevacizumab was used both for first and second line treatment (n = 83). In KRAS mutant stage 4 patients bevacizumab was used 67% of first line (n = 185), and 40.2% of second line treatments (n = 51). In KRAS wild stage 4 patients bevacizumab was used 46,8% of first line (n = 197), and 24,5% of second line treatments (n = 58). Conclusions: In this study we found that 22.9% of Turkish colorectal patients were diagnosed at Stage 4. 45% of stage 4 patients were tested for KRAS and mutatian rate was 39.3%. BRAF testing rate was low in Turkish centers. Bevacizumab was a preferred agent both for KRAS mutant and WT patients.